Antibodies Against Angiotensin II Type 1 and Endothelin 1 Type A Receptors in Cardiovascular Pathologies

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jan 21

PMID 35055116

Authors

Giovanni Civieri

Laura Iop

Francesco Tona

Affiliations

Soon will be listed here.

Abstract

Angiotensin II receptor type 1 (AT1R) and endothelin-1 receptor type A (ETAR) are G-protein-coupled receptors (GPCRs) expressed on the surface of a great variety of cells: immune cells, vascular smooth cells, endothelial cells, and fibroblasts express ETAR and AT1R, which are activated by endothelin 1 (ET1) and angiotensin II (AngII), respectively. Certain autoantibodies are specific for these receptors and can regulate their function, thus being known as functional autoantibodies. The function of these antibodies is similar to that of natural ligands, and it involves not only vasoconstriction, but also the secretion of proinflammatory cytokines (such as interleukin-6 (IL6), IL8 and TNF-α), collagen production by fibroblasts, and reactive oxygen species (ROS) release by fibroblasts and neutrophils. The role of autoantibodies against AT1R and ETAR (AT1R-AAs and ETAR-AAs, respectively) is well described in the pathogenesis of many medical conditions (e.g., systemic sclerosis (SSc) and SSc-associated pulmonary hypertension, cystic fibrosis, and allograft dysfunction), but their implications in cardiovascular diseases are still unclear. This review summarizes the current evidence regarding the effects of AT1R-AAs and ETAR-AAs in cardiovascular pathologies, highlighting their roles in heart transplantation and mechanical circulatory support, preeclampsia, and acute coronary syndromes.

Citing Articles

Circulating Autoantibodies Against Vasoactive Biomarkers Related to Orthostatic Intolerance in Long COVID Patients Compared to No-Long-COVID Populations: A Case-Control Study.

Han E, Muller-Zlabinger K, Hasimbegovic E, Poschenreithner L, Kastner N, Maleiner B Biomolecules. 2025; 15(2).

PMID: 40001603 PMC: 11853648. DOI: 10.3390/biom15020300.

Correlation and clinical significance of placental tissue selectin (E), angiotensin II and its receptors, and oxidized lipid levels in patients with preeclampsia.

Yan G, Guohong W, Haiting H, Xiaoyan L, Peifen W, Zou S J Med Biochem. 2025; 44(1):148-155.

PMID: 39991179 PMC: 11846644. DOI: 10.5937/jomb0-51303.

Autoimmunity in Cardiomyopathy-Induced Heart Failure and Cardiac Autoantibody Removal by Immunoadsorption.

Dandel M J Clin Med. 2025; 14(3).

PMID: 39941618 PMC: 11818089. DOI: 10.3390/jcm14030947.

Vascular Pathogenesis in Acute and Long COVID: Current Insights and Therapeutic Outlook.

Kruger A, Joffe D, Lloyd-Jones G, Khan M, Salamon S, Laubscher G Semin Thromb Hemost. 2024; 51(3):256-271.

PMID: 39348850 PMC: 11906225. DOI: 10.1055/s-0044-1790603.

Current and future strategies for targeting the endothelin pathway in cardiovascular disease.

Abraham G, Williams T, Maguire J, Greasley P, Ambery P, Davenport A Nat Cardiovasc Res. 2024; 2(11):972-990.

PMID: 39196099 DOI: 10.1038/s44161-023-00347-2.

References

Zhang S, Zheng R, Yang L, Zhang X, Zuo L, Yang X . Angiotensin type 1 receptor autoantibody from preeclamptic patients induces human fetoplacental vasoconstriction. J Cell Physiol. 2012; 228(1):142-8. DOI: 10.1002/jcp.24113. View

OLeary J, Philippe A, Freeman R, Heidecke H, Jennings L, Catar R . Non-HLA Autoantibodies at 1 Year Negatively Affect 5-Year Native Renal Function in Liver Transplant Recipients. Transplant Proc. 2021; 53(3):1019-1024. DOI: 10.1016/j.transproceed.2021.01.013. View

Becker M, Kill A, Kutsche M, Guenther J, Rose A, Tabeling C . Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med. 2014; 190(7):808-17. DOI: 10.1164/rccm.201403-0442OC. View

Dandona P, Dhindsa S, Ghanim H, Chaudhuri A . Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2006; 21(1):20-7. DOI: 10.1038/sj.jhh.1002101. View

Catar R, Wischnewski O, Chen L, Heidecke H, Rutz C, Schulein R . Non-HLA antibodies targeting angiotensin II Type 1 receptor and endothelin-1 Type A receptors induce endothelial injury via β2-arrestin link to mTOR pathway. Kidney Int. 2021; 101(3):498-509. DOI: 10.1016/j.kint.2021.09.029. View

Zhang Q, Reed E . The importance of non-HLA antibodies in transplantation. Nat Rev Nephrol. 2016; 12(8):484-95. PMC: 5669045. DOI: 10.1038/nrneph.2016.88. View

Philogene M, Johnson T, Vaught A, Zakaria S, Fedarko N . Antibodies against Angiotensin II Type 1 and Endothelin A Receptors: Relevance and pathogenicity. Hum Immunol. 2019; 80(8):561-567. PMC: 8015780. DOI: 10.1016/j.humimm.2019.04.012. View

Meyer L, Gong S, Reincke M, Williams T . Angiotensin II Type 1 Receptor Autoantibodies in Primary Aldosteronism. Horm Metab Res. 2020; 52(6):379-385. PMC: 7837338. DOI: 10.1055/a-1120-8647. View

Cozzi E, Calabrese F, Schiavon M, Feltracco P, Seveso M, Carollo C . Immediate and Catastrophic Antibody-Mediated Rejection in a Lung Transplant Recipient With Anti-Angiotensin II Receptor Type 1 and Anti-Endothelin-1 Receptor Type A Antibodies. Am J Transplant. 2016; 17(2):557-564. DOI: 10.1111/ajt.14053. View

10.

Dupuis J, GORESKY C, Fournier A . Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol (1985). 1996; 81(4):1510-5. DOI: 10.1152/jappl.1996.81.4.1510. View

11.

Lavoie J, Sigmund C . Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system. Endocrinology. 2003; 144(6):2179-83. DOI: 10.1210/en.2003-0150. View

12.

Bjerre A, Tangeraas T, Heidecke H, Dragun D, Dechend R, Staff A . Angiotensin II type 1 receptor antibodies in childhood kidney transplantation. Pediatr Transplant. 2016; 20(5):627-32. DOI: 10.1111/petr.12728. View

13.

Urban M, Slavcev A, Gazdic T, Ivak P, Besik J, Netuka I . The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients. Interact Cardiovasc Thorac Surg. 2015; 22(3):292-7. PMC: 4986562. DOI: 10.1093/icvts/ivv344. View

14.

Gareau A, Wiebe C, Pochinco D, Gibson I, Ho J, Rush D . Pre-transplant ATR antibodies correlate with early allograft rejection. Transpl Immunol. 2017; 46:29-35. DOI: 10.1016/j.trim.2017.12.001. View

15.

Dechend R, Homuth V, Wallukat G, Kreuzer J, Park J, Theuer J . AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation. 2000; 101(20):2382-7. DOI: 10.1161/01.cir.101.20.2382. View

16.

Wang Y, Del Borgo M, Lee H, Baraldi D, Hirmiz B, Gaspari T . Anti-fibrotic Potential of AT Receptor Agonists. Front Pharmacol. 2017; 8:564. PMC: 5583590. DOI: 10.3389/fphar.2017.00564. View

17.

Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E . Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension. 1994; 24(1):63-9. DOI: 10.1161/01.hyp.24.1.63. View

18.

Warner T, Mitchell J, Nucci G, Vane J . Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol. 1989; 13 Suppl 5:S85-8; discussion S102. DOI: 10.1097/00005344-198900135-00021. View

19.

Mehta P, Griendling K . Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2006; 292(1):C82-97. DOI: 10.1152/ajpcell.00287.2006. View

20.

Zhou C, Zhang Y, Irani R, Zhang H, Mi T, Popek E . Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008; 14(8):855-62. PMC: 3267158. DOI: 10.1038/nm.1856. View